Arca
Skip to content
Tools
Tools

Rhinitis

Drug research and approvals for rhinitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 67 studies of rhinitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 67
  • Trials authorized in Canada: 24
  • FDA orphan approvals: 0
  • EU medicines: 9

Recruiting now

Newest posted first, of 67 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 6

Phase 2 4

Phase 1 or earlier 2

How its trials ended

1,159 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 299 whose ending is known, 70% met their primary endpoint, 7% missed it and 22% stopped early.

  • Completed, result not reported65557%
  • Met its primary endpoint21018%
  • Ongoing11210%
  • Status unknown938%
  • Stopped: other or unclear343%
  • Missed its primary endpoint222%
  • Stopped: enrollment or feasibility171%
  • Stopped: sponsor or business decision101%
  • Stopped: lack of efficacy4<1%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 24; search them all in Canada trials
Nov 13, 2026Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis or…DM-101PXDesentum OyPending
Dec 31, 2025A randomized, double-blind, placebo-controlled, environmental exposure unit trial of intranasal INI-2004 in subjects with ragweed-induced allergic rhinitisINI-2004Inimmune CorporationClosed
Oct 23, 2025A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab in adult and…Lebrikizumab (LY3650150) / AzelastineEli LillyOngoing
Aug 26, 2025A two-part, adaptive, double-blind, randomized, placebo-controlled, study to assess the appropriate dose and the appropriate dosing frequency of aldp 001 in…Alcaftadine (ALDP001)Alixer Nexgen Therapeutics LtdClosed
Jul 30, 2025A phase 2, rendomized, double-blind, placebo-controlled study to investigate the safety and efficacy in reducing nasal allergen challenge provoked symptoms of…DM-101PXDesentum OyClosed
Dec 22, 2023Tezepelumab in the treatment of co-morbid allergic rhinitis and allergic asthma study (TEZARS) - an open-label exploratory mechanistic pilot study to evaluate…Tezspire / Allergen extract standardized dust mite mix/allergen extract…Kingston General Health Research InstituteOngoing
Oct 19, 2023Randomized, double-blind, cross-over clinical trial to assess onset of action and efficacy of azelastine hydrochloride 0.15% nasal spray in the treatment of…AzelastineViatrisClosed
May 24, 2023An open-label, single-dose, three-way crossover study to compare the pharmacokinetics of fixed-dose combination of mometasone + azelastine nasal spray to…Azelastine-mometasone / Azelastine / MometasoneSandozClosed
Nov 30, 2022A phase IIIb, single-center, double-blind, two-arms, placebo-controlled, randomized, parallel-group clinical trial to evaluate the efficacy and safety of 2-day…Fexofenadine (M016455)Opella Healthcare Group SASClosed
Jul 25, 2022A two-part randomized, double-blind, placebo-controlled study to assess the efficacy of the anti-bet v 1 monoclonal antibodies to reduce allergic rhinitis and…REGN5713 / REGN5714 / REGN5715RegeneronClosed

Medicines authorised in the EU

Newest first
Jan 13, 2012Desloratadine ActavisDesloratadine · genericActavis Group PTC ehfEMA ↗
Jan 13, 2012Desloratadine ratiopharmDesloratadine · genericRatiopharm GmbHEMA ↗
Nov 28, 2011DasseltaDesloratadine · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Nov 24, 2011Desloratadine TevaDesloratadine · genericTeva B.VEMA ↗
Jan 11, 2008AvamysFluticasone furoateGlaxoSmithKline Trading Services LimitedEMA ↗
Jul 30, 2007AerinazeDesloratadine; pseudoephedrineOrganon N.V.EMA ↗
Jan 15, 2001AeriusDesloratadineOrganon N.V.EMA ↗
Jan 15, 2001NeoclaritynDesloratadineOrganon N.V.EMA ↗
Jan 15, 2001AzomyrDesloratadineOrganon N.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.